BIO CEO 2012 Fireside Chat With Moncef Slaoui

  • Recommend
  • Tweet
  • Print
  • Email

Monday, February 13th, 8:00am-8:45am
 

Moncef Slaoui, PhD
Chairman, Research & Development, GlaxoSmithKline plc

Moncef became Chairman, Research & Development in June 2006. He is a member of the Board and the Corporate Executive Team. In June 2010 Moncef was given overall responsibility for GSK’s Oncology Business and over the next twelve months operational responsibiilty for GSK Biologicals will also transition to him.

In his previous position as Senior Vice President, Worldwide Business Development and External Alliances, he served on the R&D Executive Team and spearheaded recent changes in R&D to enhance drug discovery and accelerate product development. Previously, in GSK Biologicals, he engineered the development of a robust vaccines pipeline, including Rotarix, to prevent infantile gastroenteritis, and Cervarix, to prevent cervical cancer.

Following a career in academia, he has demonstrated since joining the company in 1988 that he can create a strategic vision and then vigorously pursue it to develop new products that profoundly enhance healthcare.

Moncef earned a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was Professor of Immunology at the University of Mons, Belgium. He has authored more than 100 scientific papers and presentations and is a Member of Board of the Agency for Science, Technology & Research (A*STAR). A citizen of Morocco and Belgium, he is fluent in English, French, and Arabic.

Moderator:

Stelios Papadopoulos, PhD
Co-founder & Chairman, Exelixis, Inc., and Co-Founder & Board Member, Cellzome, Inc
Dr. Stelios Papadopoulos is a co-founder and chairman of the Board of Directors of Exelixis, Inc., and he is a co-founder and a member of the Board of Directors of Cellzome, Inc. He is a member of the Board of Directors of Biogen Idec, Inc., BG Medicine, Inc., Joule Unlimited, Inc. and Regulus Therapeutics, Inc. In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé and a member of the Board of Visitors of Duke Medicine.

Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in August 2006 after six years with the firm where, as an investment banker, he focused on the biotech and pharma sectors. Prior to joining Cowen, he spent thirteen years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in April 1987 from Drexel Burnham Lambert where he was a Vice President in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was a biotechnology analyst at Donaldson, Lufkin & Jenrette.

Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with NYU Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds an MS in Physics, a PhD in biophysics and an MBA in finance, all from New York University.